Acquired factor XIII deficiency in patients under therapeutic plasma exchange: A poorly explored etiology
Introduction Factor XIII (FXIII) deficiency may cause bleeding under certain clinical circumstances. Therapeutic plasma exchange (TPE) may lead to a transient deficiency. Objectives To describe the clinical evolution of patients with acquired FXIII deficiency secondary to TPE. Methods We respectivel...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical apheresis 2021-02, Vol.36 (1), p.59-66 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 66 |
|---|---|
| container_issue | 1 |
| container_start_page | 59 |
| container_title | Journal of clinical apheresis |
| container_volume | 36 |
| creator | Chuliber, Fernando Andrés Penchasky, Diana Santoro, Diego Mario Viñuales, Susana Otero, Victoria Villagra Iturre, Maximiliano Privitera, Verónica Mezzarobba, Daniela Burgos Pratx, Leandro López, Marina Sol Barrera, Luis Schutz, Natalia Arbelbide, Jorge Martinuzzo, Marta |
| description | Introduction
Factor XIII (FXIII) deficiency may cause bleeding under certain clinical circumstances. Therapeutic plasma exchange (TPE) may lead to a transient deficiency.
Objectives
To describe the clinical evolution of patients with acquired FXIII deficiency secondary to TPE.
Methods
We respectively studied a cohort of consecutive patients from 2014 to 2019 who were treated with TPE with FXIII levels |
| doi_str_mv | 10.1002/jca.21840 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2444378145</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2444378145</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2680-10b4e9a655acdcc7ab78432e94abc591d2aeb2184341d17fa00768f6af7042fa3</originalsourceid><addsrcrecordid>eNp1kMtq20AUQIfSUDtuF_2BMtBNspAzLz2mO2PycAlk00J34mp0FY-RNfKMRKK_z7hOugh0NZfhcLj3EPKVsyVnTFztDCwFLxT7QOac6SLhnPGPZM5yKROhUj0j5yHsGGNay_QTmUmhlZBKzoldmcNoPda0ATM4T_9sNhtaY2ONxc5M1Ha0hyHOQ6BjV6OnwxY99DgO1tC-hbAHis9mC90j_qAr2jvn2yl-9a07enGwrnWP02dy1kAb8MvruyC_b65_re-S-4fbzXp1nxiRFSzhrFKoIUtTMLUxOVR5oaRAraAyqea1AKyOx0rFa543wFieFU0GTc6UaEAuyMXJ23t3GDEM5d4Gg20LHboxlEIpJfOCqzSi39-hOzf6Lm4XKc0znikhInV5oox3IXhsyt7bPfip5Kw89i9j__Jv_8h-ezWO1R7rf-Rb8AhcnYAn2-L0f1P5c706KV8Af6WO0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2491616422</pqid></control><display><type>article</type><title>Acquired factor XIII deficiency in patients under therapeutic plasma exchange: A poorly explored etiology</title><source>Access via Wiley Online Library</source><creator>Chuliber, Fernando Andrés ; Penchasky, Diana ; Santoro, Diego Mario ; Viñuales, Susana ; Otero, Victoria ; Villagra Iturre, Maximiliano ; Privitera, Verónica ; Mezzarobba, Daniela ; Burgos Pratx, Leandro ; López, Marina Sol ; Barrera, Luis ; Schutz, Natalia ; Arbelbide, Jorge ; Martinuzzo, Marta</creator><creatorcontrib>Chuliber, Fernando Andrés ; Penchasky, Diana ; Santoro, Diego Mario ; Viñuales, Susana ; Otero, Victoria ; Villagra Iturre, Maximiliano ; Privitera, Verónica ; Mezzarobba, Daniela ; Burgos Pratx, Leandro ; López, Marina Sol ; Barrera, Luis ; Schutz, Natalia ; Arbelbide, Jorge ; Martinuzzo, Marta</creatorcontrib><description>Introduction
Factor XIII (FXIII) deficiency may cause bleeding under certain clinical circumstances. Therapeutic plasma exchange (TPE) may lead to a transient deficiency.
Objectives
To describe the clinical evolution of patients with acquired FXIII deficiency secondary to TPE.
Methods
We respectively studied a cohort of consecutive patients from 2014 to 2019 who were treated with TPE with FXIII levels <50%. The FXIII was measured after the start of the TPE course, on days between the TPE sessions, due to suspected acquired deficiency. All TPE were performed using continuous flow cell separator. In all cases, the initial replacement fluid applied was albumin. Apheresis procedures were held at 24to 48 hours intervals.
Results
Eighteen patients were included, 13 of them were recipients of kidney transplants. The main TPE prescription was humoral rejection. Median FXIII at diagnosis (measured on days between sessions of the TPE course) was 19%(IQR17‐25). The median of apheresis procedures before measurement of FXIII was 3(IQR2‐4). Among the total cohort, 10 patients suffered hemorrhages. None of the patients without history of kidney transplants had bleeding (n = 5), however, 10/13 with kidney transplants did. Five kidney transplant patients received therapy with FXIII concentrate because of life‐threatening bleeding. In all cases, the bleeding stopped within the first 24 hours. All patients had their FXIII levels measured again after finishing the TPE course, with normal results.
Conclusions
TPE is an under‐diagnosed cause of acquired FXIII deficiency since routine coagulation tests remain unaltered. It might cause major bleeding, particularly in patients with a recent history of surgery like kidney transplants.</description><identifier>ISSN: 0733-2459</identifier><identifier>EISSN: 1098-1101</identifier><identifier>DOI: 10.1002/jca.21840</identifier><identifier>PMID: 32942343</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Apheresis ; bleeding ; factor XIII ; factor XIII deficiency ; Kidney transplants ; Plasma ; therapeutic plasma exchange</subject><ispartof>Journal of clinical apheresis, 2021-02, Vol.36 (1), p.59-66</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals LLC.</rights><rights>2021 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2680-10b4e9a655acdcc7ab78432e94abc591d2aeb2184341d17fa00768f6af7042fa3</citedby><cites>FETCH-LOGICAL-c2680-10b4e9a655acdcc7ab78432e94abc591d2aeb2184341d17fa00768f6af7042fa3</cites><orcidid>0000-0001-8625-8624 ; 0000-0003-1400-0899</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjca.21840$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjca.21840$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,782,786,1419,27933,27934,45583,45584</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32942343$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chuliber, Fernando Andrés</creatorcontrib><creatorcontrib>Penchasky, Diana</creatorcontrib><creatorcontrib>Santoro, Diego Mario</creatorcontrib><creatorcontrib>Viñuales, Susana</creatorcontrib><creatorcontrib>Otero, Victoria</creatorcontrib><creatorcontrib>Villagra Iturre, Maximiliano</creatorcontrib><creatorcontrib>Privitera, Verónica</creatorcontrib><creatorcontrib>Mezzarobba, Daniela</creatorcontrib><creatorcontrib>Burgos Pratx, Leandro</creatorcontrib><creatorcontrib>López, Marina Sol</creatorcontrib><creatorcontrib>Barrera, Luis</creatorcontrib><creatorcontrib>Schutz, Natalia</creatorcontrib><creatorcontrib>Arbelbide, Jorge</creatorcontrib><creatorcontrib>Martinuzzo, Marta</creatorcontrib><title>Acquired factor XIII deficiency in patients under therapeutic plasma exchange: A poorly explored etiology</title><title>Journal of clinical apheresis</title><addtitle>J Clin Apher</addtitle><description>Introduction
Factor XIII (FXIII) deficiency may cause bleeding under certain clinical circumstances. Therapeutic plasma exchange (TPE) may lead to a transient deficiency.
Objectives
To describe the clinical evolution of patients with acquired FXIII deficiency secondary to TPE.
Methods
We respectively studied a cohort of consecutive patients from 2014 to 2019 who were treated with TPE with FXIII levels <50%. The FXIII was measured after the start of the TPE course, on days between the TPE sessions, due to suspected acquired deficiency. All TPE were performed using continuous flow cell separator. In all cases, the initial replacement fluid applied was albumin. Apheresis procedures were held at 24to 48 hours intervals.
Results
Eighteen patients were included, 13 of them were recipients of kidney transplants. The main TPE prescription was humoral rejection. Median FXIII at diagnosis (measured on days between sessions of the TPE course) was 19%(IQR17‐25). The median of apheresis procedures before measurement of FXIII was 3(IQR2‐4). Among the total cohort, 10 patients suffered hemorrhages. None of the patients without history of kidney transplants had bleeding (n = 5), however, 10/13 with kidney transplants did. Five kidney transplant patients received therapy with FXIII concentrate because of life‐threatening bleeding. In all cases, the bleeding stopped within the first 24 hours. All patients had their FXIII levels measured again after finishing the TPE course, with normal results.
Conclusions
TPE is an under‐diagnosed cause of acquired FXIII deficiency since routine coagulation tests remain unaltered. It might cause major bleeding, particularly in patients with a recent history of surgery like kidney transplants.</description><subject>Apheresis</subject><subject>bleeding</subject><subject>factor XIII</subject><subject>factor XIII deficiency</subject><subject>Kidney transplants</subject><subject>Plasma</subject><subject>therapeutic plasma exchange</subject><issn>0733-2459</issn><issn>1098-1101</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kMtq20AUQIfSUDtuF_2BMtBNspAzLz2mO2PycAlk00J34mp0FY-RNfKMRKK_z7hOugh0NZfhcLj3EPKVsyVnTFztDCwFLxT7QOac6SLhnPGPZM5yKROhUj0j5yHsGGNay_QTmUmhlZBKzoldmcNoPda0ATM4T_9sNhtaY2ONxc5M1Ha0hyHOQ6BjV6OnwxY99DgO1tC-hbAHis9mC90j_qAr2jvn2yl-9a07enGwrnWP02dy1kAb8MvruyC_b65_re-S-4fbzXp1nxiRFSzhrFKoIUtTMLUxOVR5oaRAraAyqea1AKyOx0rFa543wFieFU0GTc6UaEAuyMXJ23t3GDEM5d4Gg20LHboxlEIpJfOCqzSi39-hOzf6Lm4XKc0znikhInV5oox3IXhsyt7bPfip5Kw89i9j__Jv_8h-ezWO1R7rf-Rb8AhcnYAn2-L0f1P5c706KV8Af6WO0g</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Chuliber, Fernando Andrés</creator><creator>Penchasky, Diana</creator><creator>Santoro, Diego Mario</creator><creator>Viñuales, Susana</creator><creator>Otero, Victoria</creator><creator>Villagra Iturre, Maximiliano</creator><creator>Privitera, Verónica</creator><creator>Mezzarobba, Daniela</creator><creator>Burgos Pratx, Leandro</creator><creator>López, Marina Sol</creator><creator>Barrera, Luis</creator><creator>Schutz, Natalia</creator><creator>Arbelbide, Jorge</creator><creator>Martinuzzo, Marta</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8625-8624</orcidid><orcidid>https://orcid.org/0000-0003-1400-0899</orcidid></search><sort><creationdate>202102</creationdate><title>Acquired factor XIII deficiency in patients under therapeutic plasma exchange: A poorly explored etiology</title><author>Chuliber, Fernando Andrés ; Penchasky, Diana ; Santoro, Diego Mario ; Viñuales, Susana ; Otero, Victoria ; Villagra Iturre, Maximiliano ; Privitera, Verónica ; Mezzarobba, Daniela ; Burgos Pratx, Leandro ; López, Marina Sol ; Barrera, Luis ; Schutz, Natalia ; Arbelbide, Jorge ; Martinuzzo, Marta</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2680-10b4e9a655acdcc7ab78432e94abc591d2aeb2184341d17fa00768f6af7042fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Apheresis</topic><topic>bleeding</topic><topic>factor XIII</topic><topic>factor XIII deficiency</topic><topic>Kidney transplants</topic><topic>Plasma</topic><topic>therapeutic plasma exchange</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chuliber, Fernando Andrés</creatorcontrib><creatorcontrib>Penchasky, Diana</creatorcontrib><creatorcontrib>Santoro, Diego Mario</creatorcontrib><creatorcontrib>Viñuales, Susana</creatorcontrib><creatorcontrib>Otero, Victoria</creatorcontrib><creatorcontrib>Villagra Iturre, Maximiliano</creatorcontrib><creatorcontrib>Privitera, Verónica</creatorcontrib><creatorcontrib>Mezzarobba, Daniela</creatorcontrib><creatorcontrib>Burgos Pratx, Leandro</creatorcontrib><creatorcontrib>López, Marina Sol</creatorcontrib><creatorcontrib>Barrera, Luis</creatorcontrib><creatorcontrib>Schutz, Natalia</creatorcontrib><creatorcontrib>Arbelbide, Jorge</creatorcontrib><creatorcontrib>Martinuzzo, Marta</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical apheresis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chuliber, Fernando Andrés</au><au>Penchasky, Diana</au><au>Santoro, Diego Mario</au><au>Viñuales, Susana</au><au>Otero, Victoria</au><au>Villagra Iturre, Maximiliano</au><au>Privitera, Verónica</au><au>Mezzarobba, Daniela</au><au>Burgos Pratx, Leandro</au><au>López, Marina Sol</au><au>Barrera, Luis</au><au>Schutz, Natalia</au><au>Arbelbide, Jorge</au><au>Martinuzzo, Marta</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acquired factor XIII deficiency in patients under therapeutic plasma exchange: A poorly explored etiology</atitle><jtitle>Journal of clinical apheresis</jtitle><addtitle>J Clin Apher</addtitle><date>2021-02</date><risdate>2021</risdate><volume>36</volume><issue>1</issue><spage>59</spage><epage>66</epage><pages>59-66</pages><issn>0733-2459</issn><eissn>1098-1101</eissn><abstract>Introduction
Factor XIII (FXIII) deficiency may cause bleeding under certain clinical circumstances. Therapeutic plasma exchange (TPE) may lead to a transient deficiency.
Objectives
To describe the clinical evolution of patients with acquired FXIII deficiency secondary to TPE.
Methods
We respectively studied a cohort of consecutive patients from 2014 to 2019 who were treated with TPE with FXIII levels <50%. The FXIII was measured after the start of the TPE course, on days between the TPE sessions, due to suspected acquired deficiency. All TPE were performed using continuous flow cell separator. In all cases, the initial replacement fluid applied was albumin. Apheresis procedures were held at 24to 48 hours intervals.
Results
Eighteen patients were included, 13 of them were recipients of kidney transplants. The main TPE prescription was humoral rejection. Median FXIII at diagnosis (measured on days between sessions of the TPE course) was 19%(IQR17‐25). The median of apheresis procedures before measurement of FXIII was 3(IQR2‐4). Among the total cohort, 10 patients suffered hemorrhages. None of the patients without history of kidney transplants had bleeding (n = 5), however, 10/13 with kidney transplants did. Five kidney transplant patients received therapy with FXIII concentrate because of life‐threatening bleeding. In all cases, the bleeding stopped within the first 24 hours. All patients had their FXIII levels measured again after finishing the TPE course, with normal results.
Conclusions
TPE is an under‐diagnosed cause of acquired FXIII deficiency since routine coagulation tests remain unaltered. It might cause major bleeding, particularly in patients with a recent history of surgery like kidney transplants.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>32942343</pmid><doi>10.1002/jca.21840</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8625-8624</orcidid><orcidid>https://orcid.org/0000-0003-1400-0899</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0733-2459 |
| ispartof | Journal of clinical apheresis, 2021-02, Vol.36 (1), p.59-66 |
| issn | 0733-2459 1098-1101 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2444378145 |
| source | Access via Wiley Online Library |
| subjects | Apheresis bleeding factor XIII factor XIII deficiency Kidney transplants Plasma therapeutic plasma exchange |
| title | Acquired factor XIII deficiency in patients under therapeutic plasma exchange: A poorly explored etiology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-01T12%3A35%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acquired%20factor%20XIII%20deficiency%20in%20patients%20under%20therapeutic%20plasma%20exchange:%20A%20poorly%20explored%20etiology&rft.jtitle=Journal%20of%20clinical%20apheresis&rft.au=Chuliber,%20Fernando%20Andr%C3%A9s&rft.date=2021-02&rft.volume=36&rft.issue=1&rft.spage=59&rft.epage=66&rft.pages=59-66&rft.issn=0733-2459&rft.eissn=1098-1101&rft_id=info:doi/10.1002/jca.21840&rft_dat=%3Cproquest_cross%3E2444378145%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2491616422&rft_id=info:pmid/32942343&rfr_iscdi=true |